Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Not applicable

Computational analysis of breast cancer samples from patients suggests therapeutic strategies used to treat ovarian cancer could help treat a class of basal-like breast tumors. Computational analysis of genomic and proteomic data from primary breast cancer samples identified basal-like breast tumors as a class with features similar to those of serous ovarian cancer. The data suggest patients with this class of breast tumors might benefit from treatment with poly(ADP-ribose)polymerase (PARP) inhibitors and/or platinum compounds used to treat serous ovarian cancer. Next steps could include clinical trials.
Abbott Laboratories has the PARP inhibitor veliparib in
Phase I and Phase II trials to treat multiple types of cancer.
AstraZeneca plc has the PARP inhibitor Olaparib in Phase I testing to treat brain cancer and Phase II trials to treat solid tumors.
BioMarin Pharmaceutical Inc. has BMN-673 in Phase I/II trials to treat hematologic malignancies and solid tumors.

SciBX 5(41); doi:10.1038/scibx.2012.1078
Published online Oct. 18, 2012

Unpatented; licensing status not applicable

The Cancer Genome Atlas Network. Nature; published online Sept. 23, 2012;
doi:10.1038/nature11412
Contact: Charles M. Perou, The University of North Carolina at Chapel Hill, Chapel Hill, N.C.
e-mail:
cperou@med.unc.edu